Key result
POLARx Cryoballoon achieves comparable acute LAPWI to the Arctic Front system in persistent AF.
Why the study?
Left atrial posterior wall isolation is often added to PVI for persistent AF ablation, but the feasibility and safety of a new cryoballoon ablation system for this combined approach required evaluation.
Does the novel POLARx cryoballoon system achieve comparable feasibility and safety to the Arctic Front Advance PRO system for PVI + LAPWI in patients with persistent atrial fibrillation?
Cohort (n=80)
None
None
No
Does the novel POLARx cryoballoon system achieve comparable feasibility and safety to the Arctic Front Advance PRO system for PVI + LAPWI in patients with persistent atrial fibrillation?
The novel POLARx cryoballoon system is feasible and safe for achieving PVI and LAPWI in persistent AF, with acute success rates comparable to the established Arctic Front Advance PRO system.
Supports POLARx feasibility for LAPWI in persistent AF; leaves open whether outcomes differ from Arctic Front in randomized trials.
Background Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) in the setting of persistent atrial fibrillation (AF) ablation. The aim of this study was to evaluate the feasibility and safety of a new cryoballoon ablation system in achieving PVI + LAPWI isolation. Methods The study was a prospective, non‐randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx™, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO™. Results Acute isolation was achieved in all PVs in both groups and left posterior wall isolation (LAPWI) was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between both groups, except for lower temperatures during cryoenergy in the POLARx group, for both pulmonary vein isolation (PVI) and LAPWI. Conclusion LAPWI + PVI with the novel POLARx™ Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO™ system.
No takes yet. Share an insight, caveat, or question.
Bisignani et al. (2022) conducted a cohort in Persistent atrial fibrillation (n=80). POLARx Cryoballoon ablation system vs. Arctic Front Advance PRO Cryoballoon ablation system was evaluated on Acute left atrial posterior wall isolation (LAPWI) (p=0.34). The novel POLARx Cryoballoon achieved acute left atrial posterior wall isolation in 95% of patients with persistent atrial fibrillation, comparable to the 90% success rate of the Arctic Front system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: